I have Stage IIa multifocal IDC (four foci, largest 2.4 cm, ER+, PR+, Her2-neu neg, negative sentinal nodes, grade one, Oncotype DX score 8) + DCIS in right breast. LCIS in left. Have already had wide excision; may have bilateral mastectomy. I'm 53, perimenopausal. Because of negative nodes, low grade, low Oncotype, I probably won't have chemo. My medical oncologist has asked me to consider three hormonal options: 1) standard hormonal therapy (probably tamoxifen first, then AIs, totalling five or more years); 2) TEXT trial (five yrs of triptorilen plus either tamoxifen or Aromasin); 3) standard hormonal therapy plus Lupron for up to five years. I'll of course carefully look at the survival advantages of #2 or #3 over #1 before deciding, and if they're substantial, I'll choose #2 or #3. But if the survival advantages are real but small, I'll put some weight on quality-of-life issues and might choose #1. My questions: 1. How substantially would Lupron or triptorelin (when taken in addition to tamox or AI) impact quality of life, as compared with tamox/AI alone? In other words, would there be little difference, or would the effects be magnified by a factor of 2, or more than 2? 2. Between Lupron and triptorilen, does one have quality-of-life advantages over the other? (Thanks for this excellent site.)